Cancer– tag –
-
Series: Untangling Cancer Worries — Your First GuidePart 5: Genetic Variants and Cancer Risk — What Tests Can Tell You (and What They Can’t)
Series: Untangling Cancer Worries — Your First Guide Even without medical knowledge, this series helps you calmly sort out what to check right now—for yourself or for someone you care about. When you hear “There’s a genetic variant” or “... -
Series: Untangling Cancer Worries — Your First Guide Part 4: Benign vs Malignant Tumors — What the Words Mean (and What to Confirm First)
Series: Untangling Cancer Worries — Your First Guide Even without medical knowledge, this series helps you calmly sort out what to check right now—for yourself or for someone you care about. Seeing words like “tumor,” “benign,” and “mali... -
Series: Untangling Cancer Worries — Your First Guide Part 3: What Does “Metastasis” Mean? How It Differs From Stage—and How Treatment Plans Can Change
Series: Untangling Cancer Worries — Your First Guide Even without medical knowledge, this series helps you calmly sort out what to check right now—for yourself or for someone you care about. The word “metastasis” can make people freeze. ... -
Oncology Drug Approval News Flash: Pembrolizumab plus paclitaxel with or without bevacizumab approved for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
FDA approval summary On February 10, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with... -
Series: Untangling Cancer Worries — Your First Guide Part 2: If Cancer Crosses Your Mind: 3 Things to Check First (with “When to Seek Care” signs)
Series: Untangling Cancer Worries — Your First Guide Even without medical knowledge, this series helps you calmly sort out what to check right now—for yourself or for someone you care about. The moment you think, “What if this is cancer?... -
The more important question than “present or absent”: how microbial elements may tune immunity in brain tumors
Brain tumors sit at the crossroads of immunology and microbiology, but they are also a uniquely challenging environment to study. The blood–brain barrier (BBB) and the inherently low-biomass nature of brain tissue make it difficult to me... -
Oncology Drug Approval News Flash: Daratumumab and hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone approved for newly diagnosed multiple myeloma in transplant-ineligible adults
FDA approval summary On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (V... -
Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Series Hub)
This series places women’s cancer risk on a single life-course map—from puberty and reproductive years to pregnancy/childbirth, the menopause transition, and postmenopause. We align breast, ovarian, and endometrial cancer considerations ... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 7)
Episode 7 | A Life-Course Prevention Playbook: Think in Life Events, Not Just Age—When to Seek Care, Screening Principles, and a Practical Summary Across this series, we placed breast, ovarian, and endometrial cancer risk on the same lif... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 5)
Episode 5 | Perimenopause and Menopausal Symptoms: Balancing Cancer Risk, Quality of Life, and the Role of HRT Menopause is often described as “estrogen going down,” but lived experience is usually about something else: fluctuation. Hot ... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 4
Episode 4 | Endometrial Cancer, Hormone Balance, and Metabolic Health: The “Unopposed Estrogen” Intersection “My hormones feel off” is a common phrase—useful, but often too vague to drive action. Endometrial cancer (cancer of the uterine... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column B – A Practical ADC Strategy Checklist: Ten Questions for Pharma, Biotechs, Investors, and Advisors
In Column B, we translate the themes of this series into a practical checklist for people who must make decisions about ADCs in their daily work: executives and R&D / BD leaders at pharma companies, biotechs and start-ups developing ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column A – How Enhertu Reshaped the ADC Landscape: A Case Study in Design, Clinical Strategy, and Business Impact
In Column A, we focus on Enhertu, the ADC that appears repeatedly throughout this series, and ask a simple but far-reaching question:Why did this particular ADC become such a central reference point in the current ADC land grab? We will ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 7 – Synthesis: Where We Stand in 2025 and How ADCs May Evolve Toward the 2030s
In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—antibody, payload, linker, conjugation—and discussed what people mean by first-, second-... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 6 – Designing Oncology Portfolios Beyond ADCs: Positioning Bispecifics, Cell Therapies, and Radiopharmaceuticals
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—antibody, payload, linker, conjugation—and discussed what people mean by ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 5 – The Rise of China and Asian ADC Players: How the Global Map Is Being Redrawn and Where Japan Can Stand
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examined ADC design—antibody, payload, linker, conjugation—and discussed what people mean by ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 4 – How to Read ADC Deals: M&A, Licensing, Co-development, and CDMO Agreements
In Part 1 of this series, we looked at why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examined ADC design—antibody, payload, linker, conjugation—and discussed what people mean by... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 3 – Patent Cliffs and ADCs: Why Big Pharma Wants ADCs as Growth Engines for the Next Decade
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit within the broader landscape of cancer therapies, highlighting the paradigm shift triggered by Enhertu and the evolving player landscape. In Pa... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 2 – ADC Structure and Generational Shift: What “Second- and Third-generation” ADCs Really Mean After Enhertu
In Part 1 of this series, we asked why the ADC land grab is happening now, and we positioned ADCs within the broader landscape of cancer therapies, discussed the impact of Enhertu, and looked at how pharma, biotech, and investors are rea... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 1 – Why is There an ADC Land Grab Now? Introducing ADC’s Place in Cancer Therapy
Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncology and biopharma news. Multi-billion-dollar acquisitions, mega licensing deals, capacity expansions for ADC manufacturing, and the...
